Kanuma Wins 2016 German Prix Galien Award
On October 20, 2016, Kanuma® (sebelipase alfa) received the prestigious 2016 German Prix Galien Award in the Orphan Product category, recognizing the innovation behind this novel enzyme replacement therapy for patients living with lysosomal acid lipase deficiency (LAL-D). The Prix Galien Award honors outstanding achievement in the development of new medicines, and is widely considered the highest accolade for pharmaceutical research and development.
We are privileged to receive this award, which honors not only the dedication of Alexion employees and the contributing physicians who have pushed the boundaries of science, but also the patients themselves who have the courage to face a rare and devastating disease each and every day,” said Michael Jiresch, Vice President & General Manager, Germany, at Alexion.
With the addition of this German Prix Galien Award, Alexion has now received three Prix Galien Awards since 2008. Alexion’s Soliris® (eculizumab) was granted the Prix Galien France Award in 2009 in the category of Drugs for Rare Diseases and the Prix Galien USA Award in 2008 for Best Biotechnology Product with Broad Implications for Future Biomedical Research.